score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9047	SC_9047-Tumor	
Investigate Actionability	FDA-Approved			Mutational Burden	High Mutational Burden								Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options.	Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf													0				 mutations per Mb		SC_9047		
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.L569P	0.1061	132.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763													0	302.0	0.3411	1.0	ARAF p.L569P (Missense)	0.0	SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.T206I	0.0729	96.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34													0	69.0	0.2754	0.7474	MAPK1 p.T206I (Missense)	0.0	SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.H1212Y	0.013000000000000001	461.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	SETBP1 p.H1212Y (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.H270R	0.0403	298.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	6.0	0.0	0.0001	BRCA1 p.H270R (Missense)	1.0	SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.Q69R	0.0442	249.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	22.0	0.2727	0.0244	CHEK2 p.Q69R (Missense)	0.0	SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P132H	0.0635	299.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135													0	100.0	0.37	0.8702	ERRFI1 p.P132H (Missense)	0.0	SC_9047	SC_9047-Tumor	SC_9047-Normal
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.A310T	0.0777	103.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	19.0	0.3684	0.0899	ZRSR2 p.A310T (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Y645H	0.0744	215.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.Y645H (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.S453G	0.0833	48.0	0.0	0.0																					0	205.0	0.2829	0.9922	EWSR1 p.S453G (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	NF1	Missense	p.F1413V	0.0455	220.0	0.0	0.0																					0	9.0	0.1111	0.0009	NF1 p.F1413V (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.T494A	0.0295	610.0	0.0	0.0																					0	14.0	0.0	0.0009	PDGFRB p.T494A (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R763H	0.0644	590.0	4.9e-05	0.0																					0	114.0	0.0088	0.9311	COL1A1 p.R763H (Missense)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.K511fs	0.1389	144.0	0.0	0.0																					0	0.0	0.0	0.0	ESRP1 p.K511fs (Frameshift)		SC_9047	SC_9047-Tumor	SC_9047-Normal
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 p.K511fs (Frameshift), PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: ESRP1 p.K511fs (Frameshift), PRDM2 p.703_704insP (Insertion)		SC_9047		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.317																									0				COSMIC Signature (version 2) 6 (32%)		SC_9047		
Biologically Relevant				Mutational Signature	COSMIC Signature 26	version 2	0.499																									0				COSMIC Signature (version 2) 26 (50%)		SC_9047		
